Furthermore, AAV-IL-19-GFP treatment accelerates the severity of colitis through increased DAI (Figure 7A, treatment: F(2,21)=105.6000, p<0.0010; timepoints: F(7,147)=223.3000, p<0.0010; treatment × timepoints: F(14,147)=52.0800, p<0.0010) and decreased colonic length (p<0.0010) (Figure 7B, F(2,21)=40.6300, p<0.0010). The gene discussed is IL19; the disease is colitis.